Research programme: amyloid beta protein inhibitors - AC Immune
Alternative Names: ACI-260; ACI-518; ACI-636; ACI-812; Morphomer AbetaLatest Information Update: 28 Mar 2020
At a glance
- Originator AC Immune
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Glaucoma
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for preclinical development in Glaucoma in Switzerland
- 20 Mar 2018 Morphomer abeta is still in preclinical studies for Glaucoma in Switzerland
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Switzerland